Anti-inflammatory effects of atorvastatin improve left ventricular function in experimental diabetic cardiomyopathy

[1]  S. Gardiner,et al.  Functional consequences of streptozotocin-induced diabetes mellitus, with particular reference to the cardiovascular system. , 1992, Pharmacological reviews.

[2]  J. Modrak.  Collagen Metabolism in the Myocardium from Streptozotocin-diabetic Rats , 1980, Diabetes.

[3]  C. Tschöpe,et al.  Cardiac kinin level in experimental diabetes mellitus: role of kininases. , 2003, American journal of physiology. Heart and circulatory physiology.

[4]  R. Visse,et al.  Matrix Metalloproteinases Regulation and Dysregulation in the Failing Heart , 2002 .

[5]  D. Collen,et al.  Oxidized lipoproteins in atherosclerosis and thrombosis , 1994, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[6]  N. Dhalla,et al.  Increased inhibition of SERCA2 by phospholamban in the type I diabetic heart , 2004, Molecular and Cellular Biochemistry.

[7]  A. M. Lefer,et al.  Simvastatin preserves the ischemic-reperfused myocardium in normocholesterolemic rat hearts. , 1999, Circulation.

[8]  S. Eisenberg,et al.  The metabolic fate of high density lipoprotein (HDL) in the diabetic rat , 1978, Diabetologia.

[9]  W. Bauman,et al.  Left ventricular function after chronic insulin treatment in diabetic and normal rats. , 1983, Journal of molecular and cellular cardiology.

[10]  Frits Michiels,et al.  Matrix-dependent Tiam1/Rac Signaling in Epithelial Cells Promotes Either Cell–Cell Adhesion or Cell Migration and Is Regulated by Phosphatidylinositol 3-Kinase , 1998, The Journal of cell biology.

[11]  N. Kobayashi,et al.  Cardioprotective mechanisms of Rho-kinase inhibition associated with eNOS and oxidative stress-LOX-1 pathway in Dahl salt-sensitive hypertensive rats , 2005, Journal of hypertension.

[12]  L. Chao,et al.  Kallikrein gene delivery improves serum glucose and lipid profiles and cardiac function in streptozotocin-induced diabetic rats. , 2005, Diabetes.

[13]  C. Tschöpe,et al.  Functional, biochemical, and molecular investigations of renal kallikrein-kinin system in diabetic rats. , 1999, American journal of physiology. Heart and circulatory physiology.

[14]  R. Gerszten,et al.  HMG-CoA Reductase Inhibitor Modulates Monocyte-Endothelial Cell Interaction Under Physiological Flow Conditions In Vitro: Involvement of Rho GTPase-Dependent Mechanism , 2001, Arteriosclerosis, thrombosis, and vascular biology.

[15]  N. Chang,et al.  Effect of pravastatin on development of left ventricular hypertrophy in spontaneously hypertensive rats. , 2005, American journal of physiology. Heart and circulatory physiology.

[16]  K. Preissner,et al.  The Binding Protein for Globular Heads of Complement C1q, gC1qR , 1996, The Journal of Biological Chemistry.

[17]  J. Liao,et al.  Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors. , 2001, Arteriosclerosis, thrombosis, and vascular biology.

[18]  T. Walther,et al.  Myocardial bradykinin B2‐receptor expression at different time points after induction of myocardial infarction , 2000, Journal of hypertension.

[19]  S. Zarich,et al.  Diabetic cardiomyopathy. , 1989, American heart journal.

[20]  I. Lemieux,et al.  The small, dense LDL phenotype and the risk of coronary heart disease: epidemiology, patho-physiology and therapeutic aspects. , 1999, Diabetes & metabolism.

[21]  H. Eder,et al.  Serum lipoproteins and apolipoproteins in rats with streptozotocin-induced diabetes. , 1976, The Journal of clinical investigation.

[22]  A. Ridley,et al.  Monocyte Adhesion and Spreading on Human Endothelial Cells Is Dependent on Rho-regulated Receptor Clustering , 1999, The Journal of cell biology.

[23]  D. McNamara,et al.  Contributions of Absorbed Dietary Cholesterol and Cholesterol Synthesized in Small Intestine to Hypercholesterolemia in Diabetic Rats , 1988, Diabetes.

[24]  T. Reid,et al.  Matrix-dependent Tiam 1 / Rac Signaling in Epithelial Cells Promotes Either Cell – Cell Adhesion or Cell Migration and Is Regulated by Phosphatidylinositol 3-Kinase , 1998 .

[25]  U. Laufs,et al.  HMG-CoA Reductase Inhibitors Improve Endothelial Dysfunction in Normocholesterolemic Hypertension via Reduced Production of Reactive Oxygen Species , 2001, Hypertension.

[26]  F. Villarreal,et al.  The pathogenesis of myocardial fibrosis in the setting of diabetic cardiomyopathy. , 2006, Journal of the American College of Cardiology.

[27]  B. Maisch,et al.  Metabolic basis of high density lipoproteins and apolipoprotein A-I increase by HMG-CoA reductase inhibition in healthy subjects and a patient with coronary artery disease. , 1999, Atherosclerosis.

[28]  T. Walther,et al.  Transgenic activation of the kallikrein‐kinin system inhibits intramyocardial inflammation, endothelial dysfunction, and oxidative stress in experimental diabetic cardiomyopathy , 2005, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[29]  Mu Wang,et al.  Diabetes increases formation of advanced glycation end products on Sarco(endo)plasmic reticulum Ca2+-ATPase. , 2004, Diabetes.

[30]  J. Liao,et al.  Inhibition of Rho-Kinase Leads to Rapid Activation of Phosphatidylinositol 3-Kinase/Protein Kinase Akt and Cardiovascular Protection , 2004, Arteriosclerosis, thrombosis, and vascular biology.

[31]  C. Tschöpe,et al.  Functional , biochemical , and molecular investigations of renal kallikrein-kinin system in diabetic rats , 1999 .

[32]  C. Tschöpe,et al.  Inhibition of p38 mitogen-activated protein kinase attenuates left ventricular dysfunction by mediating pro-inflammatory cardiac cytokine levels in a mouse model of diabetes mellitus , 2006, Diabetologia.

[33]  H P Schultheiss,et al.  Dilated cardiomyopathy is associated with significant changes in collagen type I/III ratio. , 1999, Circulation.

[34]  J. Loscalzo,et al.  Oxidant stress in the vasculature , 1999, Current atherosclerosis reports.

[35]  M. Dell'Acqua,et al.  Rac–MEKK3–MKK3 scaffolding for p38 MAPK activation during hyperosmotic shock , 2003, Nature Cell Biology.

[36]  K. Fujisawa,et al.  Rhotekin, a New Putative Target for Rho Bearing Homology to a Serine/Threonine Kinase, PKN, and Rhophilin in the Rho-binding Domain* , 1996, The Journal of Biological Chemistry.

[37]  J. Goldstein,et al.  Regulation of the mevalonate pathway , 1990, Nature.

[38]  A. Klip,et al.  Insulin-induced actin filament remodeling colocalizes actin with phosphatidylinositol 3-kinase and GLUT4 in L6 myotubes. , 2000, Journal of cell science.

[39]  G. King,et al.  Theoretical mechanisms by which hyperglycemia and insulin resistance could cause cardiovascular diseases in diabetes. , 1999, Diabetes care.

[40]  T. Walther,et al.  Prevention of cardiac fibrosis and left ventricular dysfunction in diabetic cardiomyopathy in rats by transgenic expression of the human tissue kallikrein gene , 2004, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[41]  M. Itoh,et al.  Statins inhibit high glucose-mediated neutrophil-endothelial cell adhesion through decreasing surface expression of endothelial adhesion molecules by stimulating production of endothelial nitric oxide. , 2003, Microvascular research.

[42]  U. Laufs,et al.  Inhibition of geranylgeranylation reduces angiotensin II-mediated free radical production in vascular smooth muscle cells: involvement of angiotensin AT1 receptor expression and Rac1 GTPase. , 2001, Molecular pharmacology.

[43]  R. B. Rawson.  The SREBP pathway — insights from insigs and insects , 2003, Nature Reviews Molecular Cell Biology.

[44]  Hiroyuki Tsutsui,et al.  Fluvastatin, a 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitor, Attenuates Left Ventricular Remodeling and Failure After Experimental Myocardial Infarction , 2002, Circulation.

[45]  S. Litwin,et al.  Abnormal cardiac function in the streptozotocin-diabetic rat. Changes in active and passive properties of the left ventricle. , 1990, The Journal of clinical investigation.

[46]  B. Davis,et al.  The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. , 1996, The New England journal of medicine.

[47]  W. Kannel,et al.  Role of diabetes in congestive heart failure: the Framingham study. , 1974, The American journal of cardiology.

[48]  F. Kummerow,et al.  Atorvastatin reduces the plasma lipids and oxidative stress but did not reverse the inhibition of prostacyclin generation by aortas in streptozotocin diabetic rats. , 2005, Prostaglandins & other lipid mediators.